Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy

In Vivo

Volumn 23, Issue 3, 2009, Pages 387-392

  Rabiau, Nadège ^a,e   Thiam, Mohamed Oury ^a   Satih, Samir ^a   Guy, Laurent ^b   Kemeny, Jean Louis ^b,c   Boiteux, Jean Paul ^b,d   Fontana, Luc ^a,c,d   Bignon, Yves Jean ^a,d   Bernard Gallon, Dominique ^a  

^a CENTRE JEAN PERRIN   (France)

^b Department of Urology ^*

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e Soluscience   (France)

Author keywords

Diagnosis; Epigenetics; MS PCR; Prostate tissues

Indexed keywords

BRCA1 PROTEIN; EPHRIN RECEPTOR B2; GLUTATHIONE TRANSFERASE P1; PROTEIN DERIVATIVE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; METHYLATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

EID: 67649858977     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prowatke: Epidemiologie et d6pistage du cancer de la prostate. 2004.
2. Hill C and Doyon F: The frequency of cancer in France in year 2000, and trends since 1950. Bull Cancer 92(1): 7-11, 2005.
3. Bauvin E, Remontet L and Grosclaude P: [Incidence and mortality of prostate cancer in France: trends between 1978 and 2000]. Prog Urol 13(6): 1334-1339, 2003.
4. Das PM and Singal R: DNA methylation and cancer. J Clin Oncol 22(22): 4632-4642, 2004.
5. Manoharan M, Ramachandran K, Soloway MS and Singal R: Epigenetic targets in the diagnosis and treatment of prostate cancer. Int Braz J Urol 33(1): 11-18, 2007.
6. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18): 9821-9826, 1996.
7. Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 23(3): 273-279, 1992.
8. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB and Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64(6): 1975-1986, 2004.
9. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC and von Ruecker A: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11(11): 4097-4106, 2005.
10. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI and Sidransky D: Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10(16): 5518-5522, 2004.
11. Ralhan R, Kaur J, Kreienberg R and Wiesmuller L: Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett 248(1): 1-17, 2007.
12. Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, Wallenstein S, Bradshaw PT, Garbowski G, Teitelbaum SL, Neugut Al, Santella RM and Chen J: BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat, 2008.
13. Wilcox CB, Baysal BE, Gallion HH, Strange MA and DeLoia JA: High-resolution methylation analysis of the BRCAI promoter in ovarian tumors. Cancer Genet Cytogenet 159(2): 114-122, 2005.
14. Yuan Y, Qian ZR, Sano T, Asa SL, Yamada 5, Kagawa N and Kudo E: Reduction of GSTPI expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. Mod Pathol 21(7): 856-865, 2008.
15. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, Nelson CP, Groopman JD and Kensler TW: Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann NY Acad Sci 952: 135-144, 2001.
16. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C and Sidransky D: Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4(1): 1-8, 2006.
17. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p2l .3. Nat Genet 25(3): 315-3 19, 2000.
18. Maat W, van der Velden PA, Out-Luiting C, Plug M, DirksMulder A, Jager MJ and Gruis NA: Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Opbthalmol Vis Sd 48(2): 486-490, 2007.
19. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espin E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr and Arango D: Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65(22): 10170-10173, 2005.